▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #638 by analyst upside · 2026-08-12
BCYC
Bicycle Therapeutics plc
Healthcare · Market Cap $288M · P/E 0x
ANALYST PRICE TARGET
+139.3%
implied upside to consensus target
Current Price $4.12
Consensus Target $9.86
Bull Target $14.0
Bear Target $5.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
2
Sell
0
52-Week Low $3.75
52-Week High $9.16
YTD Return -38.3%
FUNDAMENTALS
Market Cap $288M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.73
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $61M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.75
52-Week High $9.16
Current Price $4.12
Bear Target $5.0
Bull Target $14.0
● Now $4.12 ● Target $9.86
TRADING DATA
Avg Volume 416K
YTD Return -38.3%
Analyst Count 7
Consensus Buy
Upside to Target +139.3%
Last Updated 2026-08-12

ANALYST SUMMARY

Bicycle Therapeutics plc (BCYC) is currently trading at $4.12 with a Wall Street consensus price target of $9.86, implying potential upside of 139.3% over the next 12 months. 7 analysts currently cover BCYC, with a consensus rating of Buy - 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $5.0.

BCYC operates in the Healthcare sector with a market capitalisation of $288M. The stock is down 38.3% year-to-date and is currently trading near the lower end of its 52-week range of $3.75 – $9.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ABEO +166.4%
Abeona Therapeutics Inc.
$422M · P/E 7.8x · Buy
AGEN +185.5%
Agenus Inc.
$307M · P/E 2.3x · Buy
XFOR +171.0%
X4 Pharmaceuticals, Inc.
$424M · P/E 3.0x · Buy
CGEN +91.7%
Compugen Ltd.
$227M · P/E 6.3x · Buy
QTTB +177.4%
Q32 Bio Inc.
$459M · P/E 4.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BCYC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-04-08 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-18 14% win rate (7 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-03-18 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-18 Building track record
Needham - Reiterated
Buy → Buy 2026-03-18 20% win rate (5 calls)
Truist Securities ● Initiated
Hold 2025-11-24 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2025-10-31 Building track record
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2025-10-31 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
30
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →